Develops a drug-delivery platform that encapsulates medicines in patients’ own red blood cells for potential rare-disease treatments.
10-K for FY2025, filed Apr 10, 2026
8-K, filed Oct 9, 2026
South San Francisco, CA, October 9, 2026 – Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on…View ↗
8-K, filed Sep 14, 2026
On September 8, 2026, Quince Therapeutics, Inc. (the “Company”) completed the sale of (i) all of the issued and outstanding equity…View ↗
Drug-development focus
The older report centered on a bone-targeting drug platform for fractures and skeletal disease; the latest describes a platform that encapsulates drugs in patients’ own red blood cells for rare-disease treatment.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Apr 10, 2026Our proprietary AIDE technology platform is a novel and innovative drug/device combination that uses an automated process designed to…View ↗
Loading...